Skip to main content
Fig. 4 | Reproductive Biology and Endocrinology

Fig. 4

From: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis

Fig. 4

Relative risk for cumulative live birth rate* (a), cumulative clinical pregnancy rate (b) and cumulative ongoing pregnancy rate (c) with biosimilar preparations of follitropin alfa versus the reference product. *For the cumulative live birth, only data from the first cycle could be used for the RCT investigating Ovaleap® as all participants crossed over to the exclusive use of Ovaleap® in subsequent cycles

Back to article page

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us